Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman
November 26 2019 - 7:00AM
Business Wire
Accomplished Former COO of Deloitte Brings
Extensive Strategic, Operational and Business Expertise
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage
biopharmaceutical company addressing key mechanisms of tumor drug
resistance, today announced that it has elected Frank S. Friedman
to its Board of Directors. Mr. Friedman recently served as the
global Chief Operating Officer of Deloitte Touche Tohmatsu Limited
(Deloitte), a multinational services organization. Deciphera also
announced that Michael Ross, Ph.D., will be stepping down from its
Board of Directors.
“We are honored to have Frank join our Board of Directors, and
believe that his extensive operational and financial experience
gained over his nearly 40-year career at Deloitte will be
invaluable to Deciphera as we build our organization,” said Steve
Hoerter, President and Chief Executive Officer of Deciphera. “We
believe that his guidance will be beneficial as we continue to
advance our pipeline of novel product candidates and scale our
operations. I also want to thank Michael Ross for his guidance and
invaluable contributions to Deciphera and wish him well in his
future endeavors.”
“I’m looking forward to working with Deciphera’s distinguished
board members and impressive leadership team at this pivotal time
for the company, and to contributing to its future success,” said
Mr. Friedman. “It’s meaningful to be part of this company’s
mission, to improve the lives of cancer patients, and I’m hopeful
that both my business and board expertise will benefit Deciphera’s
business strategy as it prepares for potential growth into a
commercial stage company.”
Mr. Friedman currently serves as Chief Executive Officer at a
privately-held finance company. Previously, Mr. Friedman worked for
Deloitte from 1979 until his retirement from Deloitte in November
2019. During this time, Mr. Friedman served in several senior
officer positions at Deloitte, including as the global Chief
Operating Officer from June 2015 through June 2019. Mr. Friedman
has also served as Deloitte’s US Chief Operating Officer, from June
2015 to June 2017 and Deloitte’s US Chief Financial Officer, from
June 2011 through May 2016. Mr. Friedman served as interim U.S.
Chief Executive Officer from 2014 to 2015. Mr. Friedman received
his Bachelor of Arts in accounting and business administration from
the University of Kansas.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients by
addressing key mechanisms of drug resistance that limit the rate
and/or durability of response to existing cancer therapies. Our
small molecule drug candidates are directed against an important
family of enzymes called kinases, known to be directly involved in
the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary
chemistry library to purposefully design compounds that maintain
kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed
to address therapeutic resistance causing mutations and
immuno-targeted agents designed to control the activation of
immunokinases that suppress critical immune system regulators, and
agents designed to inhibit reprogramming of cancer cell metabolism.
We have used our platform to develop a diverse pipeline of
tumor-targeted, immuno-targeted, and metabolism-targeted drug
candidates designed to improve outcomes for patients with cancer by
improving the quality, rate and/or durability of their responses to
treatment.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding our expectations regarding future growth and scale of
operations, potential growth into a commercial company and the
potential of our pipeline product candidates to improve the lives
of patients with cancer. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to the delay of any
current or planned clinical studies or the development of our
product candidates, including ripretinib, our ability to
successfully demonstrate the efficacy and safety of our product
candidates including in later-stage studies, the preclinical and
clinical results for our product candidates, which may not support
further development of such product candidates, the possibility
that results experienced in early, preliminary, top-line or initial
data, may not be indicative of the results experienced in final
data, our ability to timely complete and prepare the information
required for and file an NDA for ripretinib, the fact that receipt
of a breakthrough therapy designation for a product candidate, such
as ripretinib, may not result in us receiving any of the benefits
of such designation, our ability to manage and our reliance on
third parties such as our third party drug substance and drug
product contract manufacturers, actions of regulatory agencies, any
or all of which may affect the initiation, timing and progress of
clinical studies and the timing of and our ability to obtain
regulatory approval, if at all, and make our investigational drugs
available to patients, and other risks identified in our SEC
filings, including our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2019, and subsequent filings with the
SEC. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. We disclaim any obligation to publicly update or revise
any such statements to reflect any change in expectations or in
events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191126005288/en/
Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc.
jrobinson@deciphera.com 781-906-1112
Media: David Rosen Argot Partners David.Rosen@argotpartners.com
212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024